Publication: BMC Infectious Diseases
Abstract
Amikacin pharmacokinetics change substantially in premature infants, yet dosing data specific to Chinese premature infants were previously unavailable. This two-center retrospective study used 54 amikacin concentrations from 23 premature infants to build a population pharmacokinetic model with Phoenix NLME and derive optimized dosing via Monte Carlo simulation. Weight, postmenstrual age, and renal function significantly influenced amikacin clearance, and the study identified three cases of acute kidney injury associated with concentrations exceeding recommended targets. The resulting model-based dosing recommendations, stratified by serum creatinine, offer an evidence-based alternative for amikacin therapy in Chinese premature infants.
Author(s): Li JH, Xu JH, Huang Y, Zhou M, Yang ZM, Li JJ, Feng ZT, Zhang Q, Yu YX, Duan LF, Tang L.
Published: 2025 年 12 月 6 日
Phoenix NLME：Dosing for Vulnerable Infants
Phoenix NLME built the population PK model behind this amikacin study in premature infants, linking dosing directly to kidney-injury risk. As part of a Phoenix platform relied on by more than 11,000 users worldwide, Phoenix NLME remains the engine behind population PK/PD modeling, combining the flexibility of code with the ease of a guided interface.
